HUMAN FAS

Abstract: Fatty Acid Synthase polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilising Fatty Acid Synthase polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Description: HUMAN FAS Field of the Invention This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides. Background of the Invention The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position. Functional genomics relies heavily on the vaπous tools of biomformatics to identify gene sequences of potential interest from the many molecular biology databases now available There is a continuing need to identify and characteπse further genes and their related polypeptides/protems, as targets for drug discovery. While the pathway for the biosynthesis of saturated fatty acids is similar in prokaryotes and eukaryotes, the organization of the biosynthetic apparatus is very different. Vertebrates and yeast possess fatty acid synthases (FASs) in which all of the enzymatic activities are encoded on one or two polypeptide chains, respectively, and the acyl carrier protein (ACP) is an integral part of the complex. In contrast, m most bacterial FASs each of the reactions are catalyzed by distinct monofunctional enzymes and the ACP is a discrete protein. There therefore is considerable potential for selective inhibition of the bacterial systems by broad spectrum antibacterial agents. Summary of the Invention The present invention relates to Fatty Acid Synthase, in particular Fatty Acid Synthase polypeptides and Fatty Acid Synthase polynucleotides, recombinant mateπals and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of cancers and bacterial infections, hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with Fatty Acid Synthase imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate Fatty Acid Synthase activity or levels. Description of the Invention In a first aspect, the present invention relates to Fatty Acid Synthase polypeptides. Such peptides include isolated polypeptides comprising an ammo acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ LD NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the ammo acid of SEQ LD NO:2. Further peptides ofthe present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO.2 over the entire length of SEQ LD NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2. Further peptides ofthe present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ LD NO: l. Polypeptides ofthe present invention are believed to be members ofthe Fatty Acid Synthase family of polypeptides. They are therefore of interest because inhibitors of FAS 1 may function as cytotoxic agents with potential as anti-cancer agents and the polypeptides of the present invention provide a tool in the development of potential novel antibacterials These properties are hereinafter referred to as "Fatty Acid Synthase activity" or "Fatty Acid Synthase polypeptide activity" or "biological activity of Fatty Acid Synthase " Also included amongst these activities are antigenic and immunogenic activities of said Fatty Acid Synthase polypeptides, in particular the antigenic and immunogenic activities ofthe polypeptide of SEQ ID NO.2 Preferably, a polypeptide of the present invention exhibits at least one biological activity of Fatty Acid Synthase The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid m purification such as multiple histidme residues, or an additional sequence for stability during recombinant production. The present invention also includes include vaπants ofthe aforementioned polypeptides, that is polypeptides that vary from the referents by conservative ammo acid substitutions, whereby a residue is substituted by another with like characteπstics. Typical such substitutions are among Ala, Nal, Leu and He; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gin; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are vaπants m which several, 5-10, 1-5, 1-3, 1-2 or 1 ammo acids are substituted, deleted, or added in any combination. Polypeptides ofthe present invention can be prepared m any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombmantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for prepaπng such polypeptides are well understood in the art. In a further aspect, the present invention relates to Fatty Acid Synthase polynucleotides Such polynucleotides include isolated polynucleotides compπsing a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to the ammo acid sequence of SEQ LD NO.2, over the entire length of SEQ LD NO:2. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide compπsing the nucleotide sequence contained in SEQ LD NO: 1 encoding the polypeptide of SEQ LD NO:2. Further polynucleotides ofthe present invention include isolated polynucleotides compπsing a nucleotide sequence that has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ LD NO.2, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Further polynucleotides ofthe present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to SEQ ID NO 1 over the entire length of SEQ LD NO: 1 In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identify are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide compπsing the polynucleotide of SEQ LD NO: 1 as well as the polynucleotide of SEQ LD NO: 1. The invention also provides polynucleotides which are complementary to all the above described polynucleotides. The nucleotide sequence of SEQ LD NO: 1 shows homology with Tumor-associated FAS (GenBank accession number: U29344). The nucleotide sequence of SEQ LD NO: 1 is a cDNA sequence and compπses a polypeptide encoding sequence (nucleotide 156 to 7688) encoding a polypeptide of 2511 ammo acids, the polypeptide of SEQ LD NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ LD NO: 1 or it may be a sequence other than the one contained in SEQ LD NO: 1 , which, as a result ofthe redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ LD NO:2. The polypeptide of SEQ LD NO:2 is structurally related to other proteins ofthe Fatty Acid Synthase family, having homology and/or structural sirmlaπty with Tumor-associated FAS (GenBank accession number: U29344). Preferred polypeptides and polynucleotides ofthe present invention are expected to have, inter aha, similar biological functions/properties to their homologous polypeptides and polynucleotides Furthermore, preferred polypeptides and polynucleotides ofthe present invention have at least one Fatty Acid Synthase activity. Polynucleotides ofthe present invention may be obtained, using standard cloning and screening techniques, from a cDNA library deπved from mRNA in cells of human testis, using the expressed sequence tag (EST) analysis (Adams, M.D., et al Science (1991) 252:1651-1656; Adams, M.D. et al , Nature, (1992) 355:632-634; Adams, M.D, et al , Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates puπfication ofthe fused polypeptide can be encoded In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidme peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al , Proc Natl Acad Set USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5 ' and 3 ' sequences, such as transcπbed, non-translated sequences, splicing and polyadenylation signals, πbosome binding sites and sequences that stabilize mRNA. Further embodiments ofthe present invention include polynucleotides encoding polypeptide vaπants which compπse the ammo acid sequence of SEQ LD NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, ammo acid residues are substituted, deleted or added, in any combination. Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained m SEQ LD NO: 1 , may be used as hybπdization probes for cDNA and genomic DNA or as pπmers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides ofthe present invention and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similaπty to SEQ LD NO: 1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that ofthe referent. The probes or pπmers will generally compπse at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. A polynucleotide encoding a polypeptide ofthe present invention, including homologs and orthologs from species other than human, may be obtained by a process which compπses the steps of screening an appropπate library under stπngent hybπdization conditions with a labeled probe having the sequence of SEQ LD NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybπdization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C m a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM tπsodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters m O lx SSC at about 65°C Thus the present invention also includes polynucleotides obtainable by screening an appropπate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ LD NO: 1 or a fragment thereof. The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, m that the region coding for the polypeptide is cut short at the 5' end ofthe cDNA This is a consequence of reverse transcπptase, an enzyme with inherently low 'processivity' (a measure ofthe ability ofthe enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis There are several methods available and well known to those skilled in the art to obtain full- length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998- 9002, 1988). Recent modifications of the technique, exemplified by the Marathon™' technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the 'missing' 5' end ofthe cDNA using a combination of gene specific and adaptor specific ohgonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' m the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design ofthe 5' primer. Recombinant polypeptides ofthe present invention may be prepared by processes well known in the art from genetically engineered host cells compπsing expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which compπse a polynucleotide or polynucleotides ofthe present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides ofthe invention by recombinant techniques Cell-free translation systems can also be employed to produce such proteins using RNAs deπved from the DNA constructs ofthe present invention. For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods descπbed in many standard laboratory manuals, such as Davis et al , Basic Methods in Molecular Biology (1986) and Sambrook et al , Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spπng Harbor Laboratory Press, Cold Spπng Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microm ection, cationic lipid- mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection Representative examples of appropπate hosts include bacteπal cells, such as streptococci, staphylococci, E colt, Streptomyces and Bacillus subtihs cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophtla S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells. A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-deπved systems, e.g., vectors derived from bacterial plasmids, from bacteπophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SN40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors deπved from combinations thereof, such as those deπved from plasmid and bacteπophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropπate nucleotide sequence may be inserted into an expression system by any of a vaπety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al, MOLECULAR CLONING, A LABORATORY MANUAL (supra). Appropπate secretion signals may be incorporated into the desired polypeptide to allow secretion ofthe translated protein into the lumen ofthe endoplasmic reticulum, the peπplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals. If a polypeptide ofthe present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced mtracellularly, the cells must first be lysed before the polypeptide is recovered. Polypeptides ofthe present invention can be recovered and puπfied from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for puπfication. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured duπng isolation and or puπfication. This invention also relates to the use of polynucleotides ofthe present invention as diagnostic reagents. Detection of a mutated form ofthe gene characteπzed by the polynucleotide of SEQ LD ΝO:l which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over- expression or altered expression ofthe gene. Individuals carrying mutations in the gene may be detected at the DNA level by a vaπety of techniques. Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, uπne, saliva, tissue biopsy or autopsy mateπal. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques pπor to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size ofthe amplified product in compaπson to the normal genotype. Point mutations can be identified by hybπdizmg amplified DNA to labeled Fatty Acid Synthase nucleotide sequences Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denatuπng agents, or by direct DNA sequencing (e.g., Myers et al, Science (1985) 230: 1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and SI protection or the chemical cleavage method (see Cotton et al , Proc Natl Acad Sci USA (1985) 85: 4397-4401 ). In another embodiment, an array of o gonucleotides probes compπsing Fatty Acid Synthase nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a vaπety of questions in molecular genetics including gene expression, genetic linkage, and genetic vaπabi ty (see for example: M.Chee et al., Science, Vol 274, pp 610-613 (1996)). The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the Fatty Acid Synthase gene by the methods descπbed. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any ofthe methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide ofthe present invention, in a sample deπved from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Thus in another aspect, the present invention relates to a diagnostic kit which comprises (a) a polynucleotide ofthe present invention, preferably the nucleotide sequence of SEQ JD NO: 1, or a fragment thereof ; (b) a nucleotide sequence complementary to that of (a); (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or (d) an antibody to a polypeptide ofthe present invention, preferably to the polypeptide of SEQ LD NO:2. It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use m diagnosing a disease or susceptibility to a disease, particularly cancers and the treatment of bacteπal infections, amongst others. The nucleotide sequences ofthe present invention are also valuable for chromosome identification. The sequence is specifically targeted to, and can hybπdize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position ofthe sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mende an Inheπtance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheπtance of physically adj acent genes) . The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease. The polypeptides ofthe invention or their fragments or analogs thereof, or cells expressing them, can also be used as lmmunogens to produce antibodies lmmunospecific for polypeptides ofthe present invention. The term "lmmunospecific" means that the antibodies have substantially greater affinity for the polypeptides ofthe invention than their affinity for other related polypeptides in the pπor art. Antibodies generated against polypeptides ofthe present invention may be obtained by admimsteπng the polypeptides or epitope-beaπng fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybπdoma technique (Kohler, G. and Milstem, C, Nature (1975) 256:495-497), the tπoma technique, the human B-cell hybπdoma technique (Kozbor et al, Immunology Today (1983) 4:72) and the EBN-hybπdoma technique (Cole et al , MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985). Techniques for the production of single chain antibodies, such as those descπbed in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies. The above-descπbed antibodies may be employed to isolate or to identify clones expressing the polypeptide or to puπfy the polypeptides by affinity chromatography. Antibodies against polypeptides ofthe present invention may also be employed to treat the Diseases, amongst others In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an lmmunoglobuhn is the constant part of the heavy chain of human IgG, particularly IgGl, where fusion takes place at the hmge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect ofthe invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. W094/29458 and W094/22914 Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide in vivo in order to induce such an immunological response to produce antibody to protect said animal from diseases. A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide ofthe present invention. The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or mtradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteπostats and solutes which render the formulation lsotomc with the blood ofthe recipient; and aqueous and non- aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored m a freeze-dπed condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity ofthe formulation, such as oil-m water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine expeπmentation. Polypeptides ofthe present invention are responsible for many biological functions, including many disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirous to devise screening methods to identify compounds which stimulate or which inhibit the function ofthe polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function ofthe polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a vaπety of sources, for example, cells, cell-free preparations, chemical hbraπes, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, ofthe polypeptide; or may be structural or functional mimetics thereof (see Coligan et al , Current Protocols in Immunology 1(2): Chapter 5 (1991)) The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition ofthe polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring Fatty Acid Synthase activity in the mixture, and compaπng the Fatty Acid Synthase activity ofthe mixture to a standard. Fusion proteins, such as those made from Fc portion and Fatty Acid Synthase polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide ofthe present invention (see D. Bennett et al., J Mol Recognition, 8:52-58 (1995); and K. Johanson et al, J Biol Chem, 270(16): 9459-9471 (1995)). FAS 1 selectivity assays Two approaches have been taken in order to identify compounds selective for bacterial vs eukaryotic fatty acid synthases, in the absence ofthe human FASl enzyme. One utilized a cleared lysate from Saccharomyces cerevisiae, the other a purified enzyme from chicken liver. Human FASl will become the selectivity assay of choice as soon as material is available and validated. Saccharomyces cerevisiae FAS 1 Yeast cells were disrupted using glass beads and cell wall debris removed by centπfugation. FASl activity was assayed in the presence of acetyl-CoA, NADPH, [^C] malonyl-CoA, DTT, and phosphate buffer. TCA precipitation and filtration was used to separate radiolabeled product from substrate. The high throughput assay conditions are: 25ul reaction volume, total counts -2000 CPM, background -100 CPM 50mM K3P04 buffer pH 6.5 45uM acetyl-CoA 150uM NADPH ImM DTT 90uM malonyl CoA (mixture of hot and cold) 44K DPM per rxn lOug/ml FAS I 37 C for 30 mm precipitate product using TCA, filter, dry and count. To confirm label was incorporated into fatty acids use the extraction assay (250-500ul volumes, same concentrations as above) then- add 0.1ml of 0.5N NaOH, 100C for 15mmutes add 0.1ml of IN HCI, followed by 2ml DI water extract 2 times m 3ml n-hexane and combine evaporate under nitrogen add cocktail and count or make the methyl esters by transesteπfication using boron triflouπde in 14% methanol and separate by TLC image by phosphor screen or autoradiography Chicken FASl Purification included liver homogenization, ammonium sulfate fractionation, gel filtration (Sephacryl S-300) and ion exchange (Q-Sepharose) chromatographies The enzyme preparation obtained is approximately 90% pure by SDS-PAGE Activity was measured in the manner outlined for the yeast assay. The activity of this enzyme was shown to be dependent on NADPH and extractable in petroleum ether, consistent with palmitate being the primary reaction product Human FASl Activity is measured in the manner outlined for the yeast assay. The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known m the art. These include, but are not limited to, ligand binding and crosshnkmg assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^^1), chemically modified (for instance, biotmylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art. Examples of potential polypeptide antagonists include antibodies or, in some cases, o gonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc, as the case may be, ofthe polypeptide, e.g., a fragment ofthe ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide ofthe present invention but do not elicit a response, so that the activity ofthe polypeptide is prevented. Thus, m another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises: (a) a polypeptide ofthe present invention, (b) a recombinant cell expressing a polypeptide of the present invention; (c) a cell membrane expressing a polypeptide of the present invention; or (d) antibody to a polypeptide of the present invention, which polypeptide is preferably that of SEQ LD NO:2 It will be appreciated that in any such kit, (a), (b), (c) or (d) may compπse a substantial component. It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used m a method for the structure -based design of an agonist, antagonist or inhibitor of the polypeptide, by: (a) determining m the first instance the three-dimensional structure of the polypeptide, (b) deducing the three-dimensional structure for the likely reactive or binding sιte(s) of an agonist, antagonist or inhibitor; (c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors. It will be further appreciated that this will normally be an interactive process In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, cancers and bacteπal infections, related to either an excess of, or an under- expression of, Fatty Acid Synthase polypeptide activity. If the activity ofthe polypeptide is in excess, several approaches are available. One approach compπses admimsteπng to a subject m need thereof an inhibitor compound (antagonist) as heremabove descπbed, optionally in combination with a pharmaceutically acceptable earner, m an amount effective to inhibit the function ofthe polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms ofthe polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the Fatty Acid Synthase polypeptide. In still another approach, expression of the gene encoding endogenous Fatty Acid Synthase polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Ohgodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, ohgonucleotides which form tπple helices with the gene can be supplied (see, for example, Lee et al , Nucleic Acids Res (1979) 6:3073; Cooney et al , Science (1988) 241 :456; Dervan et al, Science (1991) 251 :1360). These ohgomers can be administered per se or the relevant oligomers can be expressed in vivo. For treating abnormal conditions related to an under-expression of Fatty Acid Synthase and its activity, several approaches are also available. One approach compπses admmisteπng to a subject a therapeutically effective amount of a compound which activates a polypeptide ofthe present invention, i.e., an agonist as descπbed above, in combination with a pharmaceutically acceptable earner, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of Fatty Acid Synthase by the relevant cells in the subject. For example, a polynucleotide ofthe invention may be engineered for expression in a replication defective retro viral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide ofthe present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engmeeπng cells in vivo and expression ofthe polypeptide in vivo. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) m Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996) Another approach is to administer a therapeutic amount of a polypeptide ofthe present invention in combination with a suitable pharmaceutical earner. In a further aspect, the present invention provides for pharmaceutical compositions compπsing a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide ofthe present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable earner or excipient. Such earners include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits compπsmg one or more containers filled with one or more of the ingredients ofthe aforementioned compositions ofthe invention. Polypeptides and other compounds ofthe present invention may be employed alone or m conjunction with other compounds, such as therapeutic compounds. The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or mtrapentoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds ofthe present invention can be formulated in an enteπc or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like. The dosage range required depends on the choice of peptide or other compounds ofthe present invention, the route of administration, the nature ofthe formulation, the nature ofthe subject's condition, and the judgment ofthe attending practitioner. Suitable dosages, however, are in the range of 0.1-100 μg/kg of subject Wide vanations m the needed dosage, however, are to be expected in view ofthe vaπety of compounds available and the diffeπng efficiencies of vaπous routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Vanations in these dosage levels can be adjusted using standard empincal routines for optimization, as is well understood in the art. Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as descπbed above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide ex vivo, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject. Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by stoπng the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as GCC. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ LD NO: 1 and/or a polypeptide sequence encoded thereby. The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore. "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeπc, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other lmmunoglobulm expression library. "Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present m a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is "isolated", as the term is employed herein "Polynucleotide" generally refers to any polyπbonucleotide or polydeoxπbonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double- stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double- stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, fritylated bases and unusual bases such as mosine A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabohcally modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides "Polypeptide" refers to any peptide or protein comprising two or more ammo acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or ohgomers, and to longer chains, generally refeπed to as proteins. Polypeptides may contain ammo acids other than the 20 gene-encoded ammo acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known m the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature Modifications may occur anywhere m a polypeptide, including the peptide backbone, the ammo acid side-chains and the ammo or carboxyl termini It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications Polypeptides may be branched as a result of ubiquitmation, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-πbosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a hpid or lipid derivative, covalent attachment of phosphotidylmositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystme, formation of pyroglutamate, formylation, gamma- carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodmation, methylation, myπstoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of ammo acids to proteins such as arginylation, and ubiquitmation (see, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1- 12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter et al , "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol (1990) 182:626-646 and Rattan et al , "Protein Synthesis. Post-translational Modifications and Aging", Ann NYAcad Sci (1992) 663:48-62) "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs m nucleotide sequence from another, reference polynucleotide Changes m the nucleotide sequence of the variant may or may not alter the ammo acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in ammo acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ m ammo acid sequence by one or more substitutions, additions, deletions m any combination. A substituted or inserted ammo acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring vaπants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. "Identity," as known the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described m (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Hemje, G., Academic Press, 1987; and Sequence Analysis Primer, Gπbskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Caπllo, H, and Lipman, D., SIAM J. Applied Math , 48 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similaπty between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al, J. Molec. Biol 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al , NCBI NLM NLH Bethesda, MD 20894; Altschul, S., et al , J. Mol. Biol. 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity Preferred parameters for polypeptide sequence comparison include the following: 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970) Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89: 10915-10919 (1992) Gap Penalty: 12 Gap Length Penalty: 4 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps). Prefened parameters for polynucleotide comparison include the following: 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970) Comparison matrix: matches = +10, mismatch = 0 Gap Penalty: 50 Gap Length Penalty: 3 Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons. By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO: 1 , that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides m the reference sequence or in one or more contiguous groups withm the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ LD NO: 1 by the numerical percent of the respective percent ιdentιty(dιvιded by 100) and subtracting that product from said total number of nucleotides m SEQ ID NO:l, or n n < x n - (x n • y), wherein n n is the number of nucleotide alterations, x n is the total number of nucleotides m SEQ ID NO: 1 , and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0 95 for 95%,etc, and wherein any non-integer product of x n and y is rounded down to the nearest integer prior to subtracting it from x n Alterations of a polynucleotide sequence encoding the polypeptide of SEQ LD NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations. Similarly, a polypeptide sequence ofthe present invention may be identical to the reference sequence of SEQ LD NO:2, that is be 100% identical, or it may include up to a certain integer number of ammo acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one ammo acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the ammo- or carboxy-termmal positions ofthe reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the ammo acids in the reference sequence or m one or more contiguous groups withm the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of ammo acids in SEQ LD NO:2 by the numerical percent of the respective percent ιdentιty(dιvιded by 100) and then subtracting that product from said total number of ammo acids in SEQ LD NO:2, or: n a <x a - (x a • y), wherein n a is the number of ammo acid alterations, x a is the total number of amino acids in SEQ ID NO:2, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non- integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a . "Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting m, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and puπfied. All publications, including but not limited to patents and patent applications, cited this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth

Claims: What is claimed is: 1. An isolated polypeptide selected from the group consisting of: (I) an isolated polypeptide comprising an ammo acid sequence selected from the group having at least: (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity to the ammo acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2; (n) an isolated polypeptide comprising the ammo acid sequence of SEQ ID NO:2; or (in) an isolated polypeptide which is the amino acid sequence of SEQ ID NO:2. 2. An isolated polynucleotide selected from the group consisting of: (I) an isolated polynucleotide compnsmg a nucleotide sequence encoding a polypeptide that has at least (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity; to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2; (n) an isolated polynucleotide compnsmg a nucleotide sequence that has at least: (a) 70% identity (b) 80% identity; (c) 90% identity; or (d) 95% identity; over its entire length to a nucleotide sequence encoding the polypeptide of SEQ ED NO:2, (in) an isolated polynucleotide compnsmg a nucleotide sequence which has at least: (a) 70% identity; (b) 80% identity; (c) 90% identity; or (d) 95% identity; to that of SEQ ED NO: 1 over the entire length of SEQ ID NO: 1; (iv) an isolated polynucleotide compnsmg a nucleotide sequence encoding the polypeptide of SEQ LD NO:2; (v) an isolated polynucleotide which is the polynucleotide of SEQ LD NO: 1 ; or (vi) an isolated polynucleotide obtainable by screening an appropnate library under stnngent hybndization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof.; or a nucleotide sequence complementary to said isolated polynucleotide 3. An antibody lmmunospecific for the polypeptide of claim 1 4. A method for the treatment of a subject: (l) in need of enhanced activity or expression of the polypeptide of claim 1 comprising: (a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or (b) providing to the subject an isolated polynucleotide compnsmg a nucleotide sequence encoding said polypeptide in a form so as to effect production of said polypeptide activity in vivo.; or (n) having need to inhibit activity or expression of the polypeptide of claim 1 comprising: (a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or (b) administering to the subject a nucleic acid molecule that inhibits the expression of a nucleotide sequence encoding said polypeptide; and/or (c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate , or receptor. 5. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity ofthe polypeptide of claim l in a subject comprising: (a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or (b) analyzing for the presence or amount of said polypeptide expression in a sample deπved from said subject. 6. A method for screening to identify compounds which stimulate or which inhibit the function ofthe polypeptide of claim 1 which compnses a method selected from the group consisting of: (a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound, (b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor; (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide; (d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity ofthe mixture to a standard; or (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay. 7. An agonist or an antagonist ofthe polypeptide of claim 1. 8. An expression system compπsing a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell 9. A process for producing a recombinant host cell comprising transforming or transfecting a cell with the expression system of claim 8 such that the host cell, under appropriate culture conditions, produces a polypeptide comprising an ammo acid sequence having at least 70% identity to the ammo acid sequence of SEQ ID NO:2 over the entire length of SEQ ED NO:2. 10. A recombinant host cell produced by the process of claim 9. 11. A membrane of a recombinant host cell of claim 10 expressing a polypeptide comprising an ammo acid sequence having at least 70% identity to the ammo acid sequence of SEQ LD NO:2 over the entire length of SEQ ED NO:2. 12. A process for producing a polypeptide comprising cultuπng a host cell of claim 10 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture

Inventors: BERGSMA DERK J, CHAPMAN CONRAD, DEPIERA MEGAN E, ELLIS CATHERINE E, LONSDALE JOHN, MOONEY JEFFREY L, BERGSMA, DERK, J., CHAPMAN, CONRAD, DEPIERA, MEGAN, E., ELLIS, CATHERINE, E., LONSDALE, JOHN, MOONEY, JEFFREY, L.
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 2000
Main classification: A01N37
IPC codes: A61K38, A61K48, C12N9, C12Q1